Strikingly, the inhibition of HCAR1/MCT1 increases the proportion of AMP/ATP in hepatoma cells, enhances the AMP-activated protein kinase’s phosphorylation, downregulates the level of mature of sterol regulatory element-binding protein 1 and its target gene stearoyl-coenzyme A (CoA) desaturase-1, and enhances the ferroptosis sensitivity of hepatoma cells (47). Here, SLC16A1 is linked to hepatocellular carcinoma.